2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-155330
    PZ-1922 98%
    PZ-1922 (Compound 16) is a BBB-penetrable 5-HT6R/5-HT3R antagonist (Ki: 17 nM, 0.45 nM for 5-HT6R/5-HT3R respectively). PZ-1922 reversibly inhibits MAO-B (pIC50: 8.93). PZ-1922 reverses Scopolamine (SCOP) (HY-N0296) induced memory deficits in the novel object recognition (NOR) test in rats. PZ-1922 prevents Aβ-induced memory decline in the T-maze test.
    PZ-1922
  • HY-155336
    CB2R agonist 2 98%
    CB2R agonist 2 (compound cis-17-para) is a CB2R agonist.
    CB2R agonist 2
  • HY-155345
    AChE-IN-45 98%
    AChE-IN-45 (Compound 14) is an acetylcholinesterase (AChE) inhibitor with IC50 of 11.57±0.45 nM that shows antioxidant and neuroprotective activities.
    AChE-IN-45
  • HY-155355
    LY836 98%
    LY836 is an orally active neuroprotective agent. LY836 significantly blocks PSD95-nNOS association in cortical neurons. LY836 can be used in study ischemic stroke.
    LY836
  • HY-155365
    hAChE-IN-5 3007667-15-1 98%
    hAChE-IN-5 (compound 49) is a potent hAChE and hBuChE inhibitor with IC50 values of 0.17 μM and 0.17 μM, respectively. hAChE-IN-5 shows potent GSK3β inhibition with an IC50 value of 0.21 μM. hAChE-IN-5 is used as tau protein aggregation and Aβ1-42 self-aggregation inhibitor. hAChE-IN-5 can bind virtually with the PAS affecting Aβ aggregation, thus preventing Aβ-dependent neurotoxicity. hAChE-IN-5 can penetrate BBB and has the potential for multi-targeted anti-Alzheimer's agents research.
    hAChE-IN-5
  • HY-155366
    hAChE-IN-6 3007667-17-3 98%
    hAChE-IN-6 (compound 51) is a brain penetrant AChE inhibitor with an IC50 of 0.16 μM. hAChE-IN-6 also inhibits hBuChE and GSK3β with IC50 values of 0.69 μM and 0.26 μM, respectively. hAChE-IN-6 inhibits tau protein and Aβ1-42 self-aggregation, and can be used for Alzheimer's disease (AD) research.
    hAChE-IN-6
  • HY-155368
    BChE-IN-20 1428439-79-5 98%
    BChE-IN-20 (compound 7c) is a highly potent BChE-selective inhibitor and exhibits IC50s of 105 and 2.3 nM for eqBChE and hBChE, respectively. BChE-IN-20 inhibits P glycoprotein with IC50 of 0.27 μM. BChE-IN-20 is a promising template to improve design and development of BChE-selective ligands of pharmaceutical interest, including inhibitors and fluorogenic probes.
    BChE-IN-20
  • HY-155378
    PZ-1190 1852517-78-2 98%
    PZ-1190 is a multitarget ligand for serotonin and dopamine receptors with potential antipsychotic activity in rodents.
    PZ-1190
  • HY-155448
    GK56 250683-14-8 98%
    GK56 is a carboxyl nicotine hapten, which contains a linker attached to the 6-position of nicotine. GK56 conjugates to KLH via carbodiimide-mediated reactions.
    GK56
  • HY-155449
    GK60 250683-13-7 98%
    GK60 is a carboxyl nicotine hapten that can be used in the study of nicotine dependence.
    GK60
  • HY-155451
    GK83 98%
    GK83 is a carboxyl nicotine hapten that can be used in the study of nicotine dependence.
    GK83
  • HY-155466
    Boc-MIF-1-Am 98%
    Boc-MIF-1-Am (compound 2) is a human dopamine D2 receptor enhancer (EC50=17.82 nM) and is a bioconjugate of melanostatin (MIF-1) and amantadine. Boc-MIF-1-Am (200 μM) exhibited mild neurotoxicity in SH-SY5Y cells.
    Boc-MIF-1-Am
  • HY-155481
    CB2 receptor antagonist 3 98%
    CB2 receptor antagonist 3 (compound (S)-1) is an inverse agonist of the cannabinoid receptor CB2R with Kd=39 nM. CB2 receptor antagonist 3 can be used as a tool to synthesize a variety of CB2R probes.
    CB2 receptor antagonist 3
  • HY-155487
    JTE-151 1404380-58-0 99.34%
    JTE-151 is a RORγ inhibitor, which can suppress overactive immune response through inhibition of RORγ related to the activation of Th17 cells, making JTE-151 possible to be used in autoimmune disease research.
    JTE-151
  • HY-155498
    TETS-4-Methylaniline 98%
    TETS-4-Methylaniline (compound 2k) is a hapten. TETS-4-Methylaniline conjugates to the carrier protein via using either diazotization or glutaraldehyde methods.
    TETS-4-Methylaniline
  • HY-15550R
    4'-Hydroxy diclofenac (Standard) 64118-84-9
    4'-Hydroxy diclofenac (Standard) is the analytical standard of 4'-Hydroxy diclofenac. This product is intended for research and analytical applications. 4'-Hydroxy diclofenac is an orally active metabolite of Diclofenac (HY-15036) by cytochrome P450 2C9 (CYP2C9). 4'-Hydroxy diclofenac has anti-inflammatory and analgesic properties.
    4'-Hydroxy diclofenac (Standard)
  • HY-155535
    17β-HSD10-IN-2 2316765-79-2 98%
    17β-HSD10-IN-2 (compound 11) is a benzothiazolylurea-based inhibitor，targeting to 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10)，a multifunctional mitochondrial enzyme. 17β-HSD10-IN-2 don't lead to mitochondrial off-targets and cytotoxic or neurotoxic effects. 17β-HSD10 inhibitors can be used for research in Alzheimer's disease (AD) and hormone-dependent cancer.
    17β-HSD10-IN-2
  • HY-155568
    Anti-inflammatory agent 47 2925288-12-4 98%
    Flo8 is a potent anti-inflammatory and antioxidant compound. Flo8 inhibits the release of intracellular reactive oxygen species (ROS) and nitric oxide (NO) and suppresses neuronal apoptotic by inhibiting inflammatory and apoptotic signaling pathways. Flo8 can be used for Parkinson's Disease (PD) research.
    Anti-inflammatory agent 47
  • HY-155614
    KSK68 2566715-91-9 98%
    KSK68 is a high-affinity dual sigma-1 and histamine H3 receptor antagonist, with Kis of 7.7, 3.6, 22.4 nM for H3 receptor, sigma-1, sigma-2 receptor respectively. KSK68 has negligible affinity at the other histamine receptor subtypes. KSK68 can be used for research of nociceptive and neuropathic pain.
    KSK68
  • HY-155615
    KSK67 2566715-93-1 98%
    KSK67 is a high-affinity dual sigma-2 and histamine H3 receptor antagonist, with Kis of 3.2, 1531, 101 nM for H3 receptor, sigma-1, sigma-2 receptor respectively. KSK67 can be used for research of nociceptive and neuropathic pain.
    KSK67
Cat. No. Product Name / Synonyms Application Reactivity